{"schema_version":"secwatch.filing_event.v1","accession":"0001055726-25-000013","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.823482+00:00","generated_at":"2026-05-24T12:52:39.661126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025","bullets":["Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.","Cash, equivalents & investments $94.1M at Dec 31, 2024, down from $145.3M at Dec 31, 2023.","BLA for INO-3107 (RRP) on track for rolling submission mid-2025; device verification testing complete H1 2025.","DMAb interim data: 100% of participants (24/24) maintained antibody levels at week 72; no anti-drug antibodies.","Raised >$72M from ATM and two equity offerings in 2024; cash runway into Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001055726-25-000013","json":"https://secwatch.observer/filing/0001055726-25-000013.json","markdown":"https://secwatch.observer/filing/0001055726-25-000013.md","text":"https://secwatch.observer/filing/0001055726-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/0001055726-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/ino-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:52:39.661126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}